CinCor Pharma Inc. is a clinical-stage biopharmaceutical company with a mission to advance promising clinical candidates toward marketing approval. The companys focus is on cardiovascular, metabolic and kidney diseases. CinCor Pharma was founded by Jon Isaacsohn, M.D., and Catherine Pearce, DHSc, MBA, in 2018.
Company profile
Ticker
CINC
Exchange
Website
CEO
Marc de Garidel
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
CINC stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
6 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Feb 23
8-K
Completion of Acquisition or Disposition of Assets
24 Feb 23
25-NSE
Exchange delisting
24 Feb 23
SC 14D9/A
Tender offer solicitation (amended)
24 Feb 23
SC TO-T/A
Third party tender offer statement (amended)
24 Feb 23
SC 14D9/A
Tender offer solicitation (amended)
23 Feb 23
SC TO-T/A
Third party tender offer statement (amended)
23 Feb 23
8-K
Regulation FD Disclosure
21 Feb 23
SC 14D9/A
Tender offer solicitation (amended)
15 Feb 23
Latest ownership filings
SC 13D/A
Sofinnova Capital IX
3 Mar 23
SC 13D/A
Sofinnova Venture Partners X, L.P.
1 Mar 23
SC 13D/A
5AM Ventures VI, L.P.
28 Feb 23
4
Andrew J. Schwab
28 Feb 23
SC 13D/A
GENERAL ATLANTIC, L.P.
28 Feb 23
4
JAMES HEALY
27 Feb 23
4
Mason Freeman
27 Feb 23
4
David D. Allison
24 Feb 23
4
Troy A. Ignelzi
24 Feb 23
4
Michael Wayne Kalb
24 Feb 23
Financial summary
Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 292.56 mm | 292.56 mm | 292.56 mm | 292.56 mm | 292.56 mm | 292.56 mm |
Cash burn (monthly) | (no burn) | (no burn) | 7.41 mm | 6.88 mm | 6.99 mm | 7.08 mm |
Cash used (since last report) | n/a | n/a | 140.18 mm | 130.02 mm | 132.19 mm | 133.89 mm |
Cash remaining | n/a | n/a | 152.38 mm | 162.53 mm | 160.36 mm | 158.67 mm |
Runway (months of cash) | n/a | n/a | 20.6 | 23.6 | 22.9 | 22.4 |
Institutional ownership, Q1 2023
12.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 107 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 30.04 mm |
Total shares | 5.49 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
CinRx Pharma | 3.63 mm | $0.00 |
venBio Global Strategic Fund III | 1.86 mm | $30.04 mm |
General Atlantic | 0.00 | $0.00 |
Sofinnova Venture Partners X | 0.00 | $0.00 |
5AM Ventures VI | 0.00 | $0.00 |
Capital IX Sofinnova | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
24 Feb 23 | Garidel Marc de | Common Stock | Sale back to company | Dispose D | No | No | 0 | 200,000 | 0.00 | 0 |
24 Feb 23 | Garidel Marc de | Common Stock | Dispose U | No | No | 0 | 12,500 | 0.00 | 200,000 | |
24 Feb 23 | Garidel Marc de | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 7.62 | 601,901 | 4.59 mm | 0 |
24 Feb 23 | Garidel Marc de | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 5.82 | 726,483 | 4.23 mm | 0 |
24 Feb 23 | John F Thero | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 13.6 | 58,823 | 799.99 k | 0 |
24 Feb 23 | John F Thero | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 5.82 | 36,324 | 211.41 k | 0 |
24 Feb 23 | Catherine Pearce | Common Stock | Dispose U | Yes | No | 0 | 1,500 | 0.00 | 0 | |
24 Feb 23 | Catherine Pearce | Common Stock | Sale back to company | Dispose D | No | No | 0 | 15,000 | 0.00 | 0 |
24 Feb 23 | Catherine Pearce | Common Stock | Dispose U | No | No | 0 | 140,149 | 0.00 | 15,000 | |
24 Feb 23 | Catherine Pearce | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 13,236 | 0.00 | 0 |